SCHEMBL4148173

SCHEMBL4148173

COC(=O)c1sc(-c2ccc(-c3cn4ccccc4n3)cc2)cc1N(C(=O)C1CCC(C(F)(F)F)CC1)C(C)C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FASN P49327 1/20 0.42
KDM4E B2RXH2 13/20 0.41
ALDH1A1 P00352 10/20 0.41
HPGD P15428 8/20 0.41
SMN1; SMN2 Q16637 7/20 0.41
PTGS1 P23219 1/20 0.39
PTGS2 P35354 1/20 0.39
RAB9A P51151 6/20 0.38
NPC1 O15118 4/20 0.38
PKM P14618 1/20 0.38
EPHX2 P34913 1/20 0.38
ADRB2 P07550 1/20 0.38
HTT P42858 2/20 0.37
USP2 O75604 1/20 0.37
TSHR P16473 1/20 0.37
MAPK1 P28482 1/20 0.37
HSD17B10 Q99714 1/20 0.37
TP53 P04637 1/20 0.37
LMNA P02545 3/20 0.36
MAPT P10636 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4148169 1.00 FASN (0.42) FASNKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL4147205 0.92 PTGS1 (0.42) FASNKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL4147202 0.92 PTGS1 (0.42) FASNKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL4155723 0.91 KDM4E (0.43) FASNKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL4155724 0.91 KDM4E (0.43) FASNKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL4140637 0.88 TP53 (0.43) ALDH1A1HPGDSMN1; SMN2RAB9ANPC1
SCHEMBL4140640 0.88 TP53 (0.43) ALDH1A1HPGDSMN1; SMN2RAB9ANPC1
SCHEMBL4795361 0.87 FASN (0.42) FASNKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL4795366 0.87 FASN (0.42) FASNKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL4158162 0.83 KDM4E (0.35) KDM4ESMN1; SMN2RAB9ANPC1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090136448-A1 Antiviral 2-Carboxy-Thiophene Compounds CORFIELD JOHN ANDREW 2009-05-28 US disclosed
EP-1971599-A1 ANTIVIRAL 2-CARBOXY-THIOPHENE COMPOUNDS SmithKline Beecham Corporation (US) 2008-09-24 EP disclosed
WO-2007071434-A1 ANTIVIRAL 2-CARBOXY-THIOPHENE COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2007-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090136448-A1 Antiviral 2-Carboxy-Thiophene Compounds EIF2AK2, HAVCR2, MAVS FASN 3168/4885KDM4E 794/4885ALDH1A1 1037/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.